Ratings by Piper Sandler (Tyler Van Buren)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2025 | BioCryst Pharma | BCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2024 | Kronos Bio Inc. | KRON | Downgrade | Neutral (Overweight) |
0.92 (0.88) |
-4.35% | Details | |
| 11/5/2024 | Inozyme Pharma Inc. | INZY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2024 | BioCryst Pharma | BCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/14/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | MeiraGTx Holdings plc | MGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2024 | Kronos Bio Inc. | KRON | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | ESSA Pharma | EPIX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | ESSA Pharma | EPIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2024 | ESSA Pharma | EPIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/5/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2024 | Aptose Biosciences | APTO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2023 | Kronos Bio Inc. | KRON | Maintain | Overweight (N/A) |
|
Details | ||
| 6/7/2023 | Aptose Biosciences | APTO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2023 | MeiraGTx Holdings plc | MGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2023 | Aligos Therapeutics Inc. | ALGS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2023 | Aligos Therapeutics Inc. | ALGS | Upgrade | Overweight (Neutral) |
0.99 (5.59) |
464.65% | Details | |
| 11/9/2022 | Kronos Bio Inc. | KRON | Maintain | Overweight (N/A) |
|
Details | ||
| 10/19/2022 | Akouos | AKUS | Downgrade | Neutral (Overweight) |
7.01 (13.29) |
89.59% | Details | |
| 7/11/2022 | Pliant Therapeutics | PLRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Kronos Bio Inc. | KRON | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2022 | Akouos | AKUS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2022 | ESSA Pharma | EPIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2022 | Aligos Therapeutics Inc. | ALGS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/23/2022 | Aligos Therapeutics Inc. | ALGS | Downgrade | Neutral (Overweight) |
2.85 (5.59) |
96.14% | Details | |
| 3/11/2022 | Aligos Therapeutics Inc. | ALGS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2022 | Kronos Bio Inc. | KRON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2022 | Leap Therapeutics | LPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/20/2021 | Leap Therapeutics | LPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/25/2021 | Aligos Therapeutics Inc. | ALGS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2021 | Aligos Therapeutics Inc. | ALGS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/6/2021 | Aptose Biosciences | APTO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2021 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/24/2021 | Aptose Biosciences | APTO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2021 | Aligos Therapeutics Inc. | ALGS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/23/2021 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/4/2021 | ESSA Pharma | EPIX | New Coverage | Overweight (N/A) |
27.31 (0.20) |
-99.27% | Details | |
| 2/25/2021 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2021 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/17/2021 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2021 | Gracell Biotechnologies Inc | GRCL | New Coverage | Overweight (N/A) |
20.72 (10.25) |
-50.53% | Details | |
| 1/4/2021 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/28/2020 | Kinnate Biopharma | KNTE | New Coverage | Overweight (N/A) |
37.20 (2.65) |
-92.88% | Details | |
| 12/16/2020 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2020 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2020 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Overweight (N/A) |
34.40 (318.52) |
825.93% | Details | |
| 11/10/2020 | Aligos Therapeutics Inc. | ALGS | New Coverage | Overweight (N/A) |
15.09 (5.59) |
-62.96% | Details | |
| 11/5/2020 | Kura Oncology | KURA | Downgrade | Neutral (Overweight) |
32.76 (11.10) |
-66.12% | Details | |
| 11/5/2020 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2020 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2020 | Kronos Bio Inc. | KRON | New Coverage | Overweight (N/A) |
28.09 (0.92) |
-96.72% | Details | |
| 10/26/2020 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/5/2020 | Eidos Therapeutics | EIDX | Downgrade | Neutral (Overweight) |
51.92 (122.21) |
135.38% | Details | |
| 9/21/2020 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2020 | Inozyme Pharma Inc. | INZY | New Coverage | Overweight (N/A) |
29.00 (4.00) |
-86.21% | Details | |
| 8/18/2020 | Nurix | NRIX | New Coverage | Overweight (N/A) |
23.88 (23.97) |
0.38% | Details | |
| 8/12/2020 | TCR2 Therapeutics | TCRR | New Coverage | Overweight (N/A) |
16.94 (1.48) |
-91.26% | Details | |
| 7/29/2020 | Momenta Pharmaceuticals | MNTA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2020 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2020 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2020 | Akouos | AKUS | New Coverage | Overweight (N/A) |
21.12 (13.29) |
-37.07% | Details | |
| 6/29/2020 | Pliant Therapeutics | PLRX | New Coverage | Overweight (N/A) |
31.08 (1.17) |
-96.24% | Details | |
| 6/29/2020 | Leap Therapeutics | LPTX | New Coverage | Overweight (N/A) |
2.23 (2.06) |
-7.62% | Details | |
| 6/23/2020 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2020 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2020 | BioCryst Pharma | BCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2020 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2020 | Harpoon Therapeutics | HARP | New Coverage | Overweight (N/A) |
19.20 (23.01) |
19.84% | Details | |
| 5/13/2020 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2020 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
12.36 (0.17) |
-98.62% | Details | |
| 3/20/2020 | Gilead Sciences | GILD | Upgrade | Overweight (Neutral) |
78.55 (131.27) |
67.12% | Details | |
| 2/28/2020 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2020 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2020 | Eidos Therapeutics | EIDX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2020 | Kura Oncology | KURA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2020 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2020 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 1/10/2020 | Neoleukin Therapeutics | NLTX | New Coverage | Overweight (N/A) |
9.94 (3.49) |
-64.89% | Details | |
| 11/25/2019 | Oyster Point Pharma | OYST | New Coverage | Overweight (N/A) |
14.50 (11.17) |
-22.97% | Details | |
| 11/13/2019 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2019 | Nektar Therapeutics | NKTR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2019 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/1/2019 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 9/26/2019 | Rocket Pharmaceuticals | RCKT | New Coverage | Overweight (N/A) |
12.65 (3.84) |
-69.64% | Details | |
| 9/3/2019 | MeiraGTx Holdings plc | MGTX | New Coverage | Overweight (N/A) |
20.25 (13.92) |
-31.26% | Details | |
| 8/9/2019 | Nektar Therapeutics | NKTR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Adverum Biotechnologies | ADVM | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2019 | Eidos Therapeutics | EIDX | New Coverage | Overweight (N/A) |
36.33 (51.92) |
42.91% | Details | |
| 7/22/2019 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
26.00 (77.19) |
196.88% | Details | |
| 6/4/2019 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2019 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/17/2019 | Adverum Biotechnologies | ADVM | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2019 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2019 | Allogene | ALLO | New Coverage | Overweight (N/A) |
26.19 (2.08) |
-92.06% | Details | |
| 3/11/2019 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2019 | Ovid Therapeutics Inc | OVID | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2019 | Nektar Therapeutics | NKTR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2019 | Ionis Pharmaceuticals | IONS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/15/2019 | Mirati Therapeutics | MRTX | New Coverage | Overweight (N/A) |
72.19 (58.70) |
-18.69% | Details | |
| 2/12/2019 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/12/2019 | Nektar Therapeutics | NKTR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2018 | PolarityTE | PTE | New Coverage | Overweight (N/A) |
13.45 (0.24) |
-98.22% | Details | |
| 12/6/2018 | bluebird bio | BLUE | Downgrade | Neutral (Overweight) |
113.65 (4.97) |
-95.63% | Details | |
| 11/16/2018 | BioCryst Pharma | BCRX | New Coverage | Overweight (N/A) |
6.99 (9.84) |
40.77% | Details | |
| 11/9/2018 | Kura Oncology | KURA | New Coverage | Overweight (N/A) |
12.09 (32.76) |
170.97% | Details | |
| 11/2/2018 | Adverum Biotechnologies | ADVM | Maintain | Overweight (N/A) |
|
Details | ||
| 10/26/2018 | Gilead Sciences | GILD | Downgrade | Neutral (Overweight) |
68.01 (131.27) |
93.02% | Details | |
| 9/28/2018 | Otonomy | OTIC | New Coverage | Overweight (N/A) |
2.75 (2.22) |
-19.27% | Details | |
| 9/12/2018 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2018 | Crinetics | CRNX | New Coverage | Overweight (N/A) |
29.84 (42.23) |
41.52% | Details |
